Q-omics provides the consensus-scored HRH4 profile across patient tissues and cancer cell-line models. HRH4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, HRH4 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, HRH4 RNA expression shows 15,141 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, KIRC, and UVM as cancer lineages where HRH4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HRH4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HRH4 survival associations across molecular data types. HRH4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HRH4 RNA expression–survival associations across cancer types. High HRH4 expression shows unfavorable associations in UCEC, UVM, STAD, LGG and THCA, but favorable associations in HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for HRH4 RNA expression.
This table summarizes HRH4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HRH4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HRH4 shows lower tumor expression in BRCA, LUSC, PAAD and UCEC and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher HRH4 RNA expression in tumor versus normal tissue (log2 FC = +0.093, t-test p < 0.001).
This table shows molecular features associated with HRH4 in patient tissues and cancer cell lines. In patient samples, HRH4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HRH4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
